| Second lung cancers in patients after treatment for an initial lung cancer. | |
| | |
MedLine Citation:
|
PMID: 9747865 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Prospectively and retrospectively identified patient cohorts that were successfully treated for primary lung cancer have been followed to document the rate of development of and the effectiveness of treatment of second lung cancers. This review was performed to assess rates of second lung cancer development, factors associated with the development of these cancers, and the success of their treatment. METHODS: The MEDLINE database was searched to identify articles published in English concerning lung cancers, second primary cancers, treatment of these cancers, and patient survival. RESULTS: The risk of developing a second lung cancer in patients who survived resection of a non-small-cell lung cancer is approximately 1%-2% per patient per year. Approximately one half of the patients who develop second non-small-cell lung cancers can have these tumors resected. The median survival from diagnosis of a second lung cancer in these patients is between 1 and 2 years, with a 5-year survival of approximately 20% (range, 4%-32%). The average risk of developing a second lung cancer in patients who survived small-cell lung cancer is approximately 6% per patient per year. For patients who survived small-cell cancer, the risk increases from approximately 2% to greater than 10% per patient per year 10 years after initial treatment. Only 7% (range, 6%-12%) of patients treated for small-cell lung cancer survive 2 years or more. Survivors who continue to smoke cigarettes have an increased risk of developing a second lung cancer. CONCLUSIONS: In patients surviving an initial lung cancer, the cumulative risk for the development of a second primary lung cancer makes this cancer a common cause of death. The high risk of developing a second lung cancer makes patients with these cancers an important population for study of surveillance strategies and chemoprevention agents. |
| | |
Authors:
|
B E Johnson |
Related Documents
:
|
17086525 - Incidental findings with cardiac ct evaluation: should we read beyond the heart? 11217455 - Molecular pathology of lung cancer. 8217235 - Survival rates in lung cancer patients with and without bronchial asthma. 2295125 - Isoenzyme(s) of glutathione transferase (class mu) as a marker for the susceptibility t... 20702055 - "i wish i'd told them": a qualitative study examining the unmet psychosexual needs of p... 8885795 - Cytopathology of false negatives preceding cervical carcinoma. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of the National Cancer Institute Volume: 90 ISSN: 0027-8874 ISO Abbreviation: J. Natl. Cancer Inst. Publication Date: 1998 Sep |
Date Detail:
|
Created Date: 1998-09-29 Completed Date: 1998-09-29 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 7503089 Medline TA: J Natl Cancer Inst Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1335-45 Citation Subset: IM |
Affiliation:
|
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889-5105, USA. bj16b@nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Non-Small-Cell Lung
/
secondary,
therapy Carcinoma, Small Cell / secondary, therapy Humans Lung Neoplasms / secondary*, therapy* Neoplasms, Second Primary / etiology* Population Surveillance Risk |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Maize mitochondrial seryl-tRNA synthetase recognizes Escherichia coli tRNA(Ser) in vivo and in vitro...
Next Document: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.